Previous close | 0.1100 |
Open | 0.1050 |
Bid | 0.1050 x N/A |
Ask | 0.0000 x N/A |
Day's range | 0.1050 - 0.1100 |
52-week range | 0.0650 - 0.1700 |
Volume | |
Avg. volume | 987,456 |
Market cap | N/A |
Beta (5Y monthly) | 1.06 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0200 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Highlights: Immuron proceeding to Phase 3 registration strategy with the FDATravelan® topline clinical trial results demonstrate protective efficacy with single daily dose36.4% protective efficacy against Enterotoxigenic Escherichia coli (ETEC) induced moderate to severe diarrhea was observed in the Travelan® group compared to the placebo group (primary endpoint)66.7% protective efficacy against ETEC induced severe diarrhea was observed in the Travelan® group compared to the placebo group (secon
Highlights: Travelan® sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5 millionAustralian Travelan® YTD Jan 2024 sales $2.1 millionUSA Travelan® YTD Jan 2024 sales $0.6 millionCanadian sales recommenced through McKesson MELBOURNE, Australia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record sales (unaudited net sales) of Travelan®, an over-the-co